Suxamethonium
As of the edition of 20 October 2026, Suxamethonium is a small molecule: marketed, first approved in 1952 (CA); acts on CHRNA1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2001
- Kind
- Small molecule
- Brand name
- Anectine
- First approved
- 31 December 1952 (CA)
- Approvals on record
- 13 in 3 regions
- Holder of the most recent approval
- Hikma Pharmaceuticals; 6 holders in all
- Registered trials
- 13, 0 stopped early
- Disease areas
- Nervous system; Lungs and airways; Bones, joints and muscles; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRNA1 | Acetylcholine receptor subunit alpha | P02708 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 4 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 7 | 6 | 0 | 0 |
| All trials | 13 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Acquired holder | 1952 to now |
| Bristol Myers Squibb | Acquired holder and Later holder | 2003 to now |
| Sandoz | Acquired holder | 2017 to now |
| Hikma Pharmaceuticals | Later holder | 2021 to now |
| Abbott | Later holder | |
| Concentra Biosciences | Applicant |